Nuclear
medicine/radiopharmaceuticals is expected to
grow, owing to factors such as rising prevalence of chronic diseases, alpha
radioimmunotherapy-based targeted oncology treatment and advancement in imaging
technologies using radiopharmaceuticals play vital role in the growth of the
radiopharmaceuticals market. However, the restraints such as short shelf-life
of radiopharmaceuticals and availability of substitutes of radiopharmaceuticals
are likely to impact the growth of the market in the forecast period.
A
radiopharmaceutical is a drug, which can be used either for diagnostic or
therapeutic purposes. Radiopharmaceuticals are radioisotopes that are bound to
biological molecules that target specific tissues, organs, or cells within the
human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging
where the radiation escapes the body. These rays are detected by a specific
device, which is usually single-photon emission computed tomography (SPECT)/
positron emission tomography (PET) cameras.
The shelf-life or expiry date of a
radiopharmaceutical preparation depends mainly on the half-life of
the radioisotope, the radiochemical stability and the content of
longer-lived radiopharmaceutical preparations contain radioisotopes with
very short radionuclide impurities in the
preparation under consideration. Most of the require
an expiry date and time to be indicated. For example, technetium based half-lives and such preparations have very short
shelf-lives. These preparationsintended to be used within less than 12 hours,
or sometimes within few minutespreparations and positron emission tomography
(PET) preparations are generallyof preparation. Hence, the short shelf-life of
radiopharmaceuticals are expected to hinder
the growth of the market in the future years.
Download Sample PDF
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as stock market, massive slowing of supply chain, falling business confidence, and affecting the supply chain. The COVID-19 crisis is creating uncertainty in the increasing panic among the customer segments. As government of different hinder the overall NUCLEAR MEDICINE/RADIOPHARMACEUTICALS market globally. This report on ‘NUCLEAR MEDICINE/RADIOPHARMACEUTICALS market’ provides the analysis on impact on Covid-19 on various business segments and regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, country markets.
Market share of Nuclear Medicine/Radiopharmaceuticals Market is dominated by companies like
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as stock market, massive slowing of supply chain, falling business confidence, and affecting the supply chain. The COVID-19 crisis is creating uncertainty in the increasing panic among the customer segments. As government of different hinder the overall NUCLEAR MEDICINE/RADIOPHARMACEUTICALS market globally. This report on ‘NUCLEAR MEDICINE/RADIOPHARMACEUTICALS market’ provides the analysis on impact on Covid-19 on various business segments and regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, country markets.
Market share of Nuclear Medicine/Radiopharmaceuticals Market is dominated by companies like
- Cardinal Health
- IBA Worldwide
- Curium
- GENERAL ELECTRIC
- Bayer AG
- Positron
- NTP Radioisotopes SOC
- Bracco
- Lantheus Medical Imaging
- Advanced Accelerator Applications
No comments:
Post a Comment